EMA committee backs Lilly’s obesity pill as the oral GLP-1 race widens
The EMA's human medicines committee recommended approval of Lilly's once-daily orforglipron pill on Oct. 15, as Viking started Phase 3 trials of oral VK2735 and Nature Medicine reported a Phase 3 trial of safiglipron.
